Metabolic & Cardiometabolic
GLP-1 receptor agonists improves MASH / NASH (steatohepatitis)
In plain terms: Can GLP-1 drugs help fatty-liver disease (MASH/NASH), including the scarring?
Strong support Metabolic & Cardiometabolic
Part of: 💊 GLP-1 Drugs
RefutedContestedStrong support
consensus score 0.76
Yes for resolving the inflammation — robustly shown for semaglutide and tirzepatide; the harder fibrosis (scarring) benefit was null in early phase-2 but reached significance in the large phase-3 ESSENCE trial.
📅 Last reviewed: 2026-07-15 ⓘ
Evidence ladder
How far up the ladder this claim has climbed. A high consensus on a low rung means "consistent so far," not "proven in people."
Top evidence so far: All trials, pooled (Meta-analysis)
MechanismIn-vitroAnimalObservationalRCTMeta-analysis
How the studies fall
24 support 0 contradict 0 tested null 3 mixed · 27 sources, 24 independent groups · 2 superseded — pooled inside a review, counted once
The evidence (29)
| Source | Grade | Stance | Quality | Finding |
|---|---|---|---|---|
| Alzaki 2026 · Cureus | RCT | supports | high | Across seven biopsy-confirmed MASH RCTs, GLP-1 (semaglutide) and GIP/GLP-1 (tirzepatide) agonists improved histologic MASH resolution, with semaglutide achieving dual endpoints in phase 3 ESSENCE. |
| Suresh MG et al 2026 · study_type: observational | observational | supports | low | Narrative review of MASLD/T2DM: GLP-1 receptor agonists (among other antidiabetic agents) show hepatic benefits beyond glycemic control as part of emerging pharmacotherapy landscape. |
| Khalifa O et al 2026 · study_type: observational | observational | supports | moderate | Comprehensive narrative review from GLP-1 discovery to FDA approval: extensive mechanistic, preclinical, and clinical evidence show GLP-1RAs reduce hepatic steatosis, attenuate inflammation, and impede disease progression, established as th |
| Armstrong 2016 · Lancet | RCT | supports | moderate | LEAN phase-2: liraglutide steatohepatitis resolution 39% vs 9% placebo with no fibrosis worsening; small (n=52). ↩ SUPERSEDED — pooled in the review above, counted once |
| Sun 2024 · Drugs | meta-analysis | supports | moderate | 24-wk NAFLD NMA: GLP-1RA improve hepatic steatosis/enzymes vs placebo; shorter horizon limits fibrosis read. |
| Tang M et al 2026 · study_type: meta-analysis | meta-analysis | supports | high | Frequentist network meta-analysis of 34 studies/33 RCTs (Phase II/III, biopsy-proven MASH): GLP-1/GIP dual agonists had the highest MASH-resolution efficacy (RR 5.21) and GLP-1 RAs alone improved fibrosis (RR 1.51, 95% CI 1.09-2.10) versus |
| Malandris K et al 2026 · study_type: observational | observational | supports | low | Narrative review: GLP-1 RAs and dual GIP/GLP-1 RAs demonstrate 'meaningful benefits' in steatohepatitis; semaglutide provides the most robust evidence for fibrosis benefit, with potential antifibrotic effects also for tirzepatide. |
| McGuire 2025 · N Engl J Med | RCT | supports | low | SOUL (CV trial) supports systemic cardiometabolic benefit relevant to liver-heart axis; not a liver-histology endpoint. |
| Newsome 2021 · N Engl J Med | RCT | mixed | moderate | Authors' reply reaffirming phase-2 result: strong NASH resolution, fibrosis endpoint not met — honest limitation. |
| Weng J et al 2026 · study_type: observational | observational | supports | low | Retrospective cohort (n=229 MASLD patients on GLP-1 RAs, 29 with baseline FIB-4≥1.3): mean FIB-4 decreased from 1.94 to 1.73 over 12 months (95% CI -0.38 to -0.05, P=0.019), with significant AST/ALT/BMI/A1c reductions; FIB-4 improvement ind |
| Lin RT et al] # corrected 2026-08-17 from PubMed; was [Zhou 2024 · Metabolism | meta-analysis | mixed | high | NMA of MASLD drugs: GLP-1RA and polyagonists improve histology/resolution; THR-beta/FGF21 stronger for fibrosis specifically. |
| Newsome 2025 · N Engl J Med | RCT | supports | high | ESSENCE phase-3 (240wk): semaglutide 2.4mg — steatohepatitis resolution 62.9% vs 34.3% AND fibrosis improvement 36.8% vs 22.4% (both P<0.001). |
| Mahoon D et al 2026 · study_type: meta-analysis | RCT | supports | moderate | Systematic review (PROSPERO CRD420261337353) of 12 studies: GLP-1RAs (semaglutide, liraglutide, dulaglutide, beinaglutide) most consistently reduced hepatic fat, with strongest histological benefit for steatohepatitis resolution in non-cirr |
| Tsakiridis EE et al 2026 · study_type: mechanism | observational | supports | moderate | Mechanistic review: GLP-1-based therapies consistently improve steatosis and steatohepatitis via reduced hepatic nutrient flux, improved adipose insulin sensitivity, and weight-independent anti-inflammatory effects, despite limited direct h |
| Loomba 2024 · N Engl J Med | RCT | supports | high | SYNERGY-NASH: tirzepatide MASH resolution 44-62% vs 10% placebo (dose-dependent, P<0.001); fibrosis signals favorable. ↩ SUPERSEDED — pooled in the review above, counted once |
| Dos Santos Borges R et al] # corrected 2026-08-17 from PubMed; was [2026 venue: JHEP Rep · JHEP Rep | meta-analysis | supports | high | SR/MA of GLP-1RA in MASH w/ fibrosis: consistent steatohepatitis resolution; pooled fibrosis benefit now emerging. |
| Abenavoli L et al 2026 · study_type: observational | observational | supports | low | Narrative review: GLP-1 receptor agonists reduce hepatic steatosis, inflammation, and fibrosis-related biomarkers, primarily via weight loss and improved insulin sensitivity; dual GLP-1/GIP agonists (tirzepatide) show superior outcomes; fib |
| Damen 2026 · Ann Intern Med | meta-analysis | supports | moderate | ACP review notes obesity pharmacotherapy improves obesity-linked steatotic liver disease markers. |
| Tornea DA et al 2026 · study_type: meta-analysis | meta-analysis | supports | high | Systematic review and meta-analysis of 20 RCTs: GLP-1 agonists significantly increased MASH resolution without fibrosis worsening (RR 3.03, p<0.0001) and fibrosis improvement by ≥1 stage (RR 1.45, p<0.00001) overall, but in patients without |
| Pantea I et al 2026 · study_type: observational | observational | supports | moderate | Bibliometric + evidence review of tirzepatide: SYNERGY-NASH trial showed high rates of MASH resolution without fibrosis worsening and 'meaningful fibrosis regression' at 52 weeks; EASL-EASD-EASO guidelines recommend tirzepatide for MASLD wi |
| Amorim 2026 · Chronic Dis Transl Med | observational | supports | moderate | Review: liraglutide (LEAN), semaglutide (phase-2/ESSENCE), tirzepatide (SYNERGY) all improve MASH; durability of fibrosis benefit a gap. |
| Dinkov B et al 2026 · study_type: observational | observational | supports | moderate | Narrative review (33 studies): tirzepatide achieved MASH resolution in 44-62% of patients in phase 2 SYNERGY-NASH; semaglutide FDA-approved for MASH with fibrosis based on Phase 3 ESSENCE trial; preclinical data show gut-microbiome-mediated |
| Zacharia GS et al 2025 · study_type: observational | observational | supports | moderate | Narrative review: semaglutide therapy is associated with resolution of steatohepatitis and improvement in hepatic fibrosis; approved (with resmetirom) for non-cirrhotic MASH with moderate-to-advanced fibrosis. |
| Choi S et al 2026 · study_type: mechanism | observational | supports | low | Mechanistic review proposing an AMPK-centric framework for MASH therapeutics: GLP-1 receptor agonists (e.g., semaglutide) are framed as acting predominantly through systemic effects (weight loss, glycemic control) converging on AMPK activat |
| Mahalingam S et al 2026 · study_type: observational | observational | supports | low | Narrative review: GLP-1 RAs' efficacy in resolving MASH is 'increasingly well documented,' via weight loss, improved insulin sensitivity, reduced hepatic lipogenesis, and anti-inflammatory/AMPK-mediated effects; extension to ALD/MetALD and |
| Wang MJ et al 2026 · study_type: meta-analysis | meta-analysis | supports | high | PRISMA systematic review + meta-analysis of 25 RCTs (n=2481): GLP-1 RAs significantly increased MASH resolution without fibrosis worsening (OR 4.04, 95% CI 2.69-6.05, high GRADE certainty) but showed no significant fibrosis improvement (OR |
| Newsome 2021 · N Engl J Med | RCT | mixed | high | Phase-2 semaglutide: NASH resolution 59% vs 17% placebo (P<0.001) BUT fibrosis improvement not significant (43% vs 33%, P=0.48). |
| Villaseñor-Tapia EC et al 2026 · study_type: observational | observational | supports | low | Narrative review: GLP-1 receptor agonists show 'clinically meaningful improvements' in metabolic parameters and hepatic steatosis, though impact on fibrosis and long-term disease modification remains uncertain. |
| Cruz AM et al 2026 · study_type: meta-analysis | RCT | supports | high | Systematic review of clinical studies: semaglutide phase 3 achieved MASH resolution w/o fibrosis worsening in 62.9% vs 34.3% placebo (p<0.001); phase 2 NASH resolution 59% vs 17% (p<0.001) but no significant fibrosis improvement (43% vs 33% |
Disagree, or know a study we missed?
We grade by evidence, not opinions. The way to weigh in is to point us to a study we haven't cited (check the evidence table above first), or to flag a problem with one we have. Every submission is reviewed; if it holds up, the grade updates and shows in Science Changes Its Mind.
Opens a short form. You'll sign in with Google so submissions are tied to a real account — we don't display your identity, and we only accept a link we can verify (PubMed, DOI, ClinicalTrials.gov).
Educational only, not medical advice. Grades and scores reflect published evidence weighted by study design and quality; see the methodology.